TNFRSF13B Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The TNFRSF13B gene encodes the TACI receptor, a critical regulator of B-cell survival, isotype switching, and antibody production, primarily mediating signals from BAFF and APRIL.
• Pathogenic variants in TNFRSF13B are a frequent monogenic cause of Common Variable Immunodeficiency (CVID) and IgA Deficiency (IgAD), characterized by recurrent bacterial infections and often accompanied by autoimmune complications.
• TACI signaling is essential for class switch recombination (CSR) to IgA and IgG and for T-independent antibody responses to polysaccharide antigens, with mutations leading to impaired vaccine responses.
• The most common pathogenic variants, C104R and A181E, disrupt TACI's extracellular ligand-binding domains or stalk region, leading to reduced receptor expression or impaired BAFF/APRIL binding and signaling.
• TNFRSF13B variants are associated with increased susceptibility to viral infections, including EBV and SARS-CoV-2, and have been implicated in certain hematological malignancies and pulmonary arterial hypertension.
• Treatment for TNFRSF13B-associated immunodeficiency primarily involves immunoglobulin replacement therapy (IVIG/SCIG) and prophylactic antibiotics to manage recurrent infections.

Executive Summary & Key Metadata

The TNFRSF13B gene (Tumor Necrosis Factor Receptor Superfamily Member 13B) encodes the transmembrane activator and CAML interactor (TACI) protein, a critical type III transmembrane receptor predominantly expressed on B lymphocytes. TACI serves as a central node in humoral immunity, mediating signals from the TNF superfamily cytokines BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). Its functions span B-cell survival, isotype switching, plasma cell differentiation, and the regulation of T-independent antibody responses. Pathogenic variants in TNFRSF13B are among the most frequently identified monogenic causes of Common Variable Immunodeficiency (CVID) and IgA deficiency (IgAD), though penetrance is incomplete and expressivity is highly variable. Beyond primary immunodeficiency, TNFRSF13B variants have been implicated in autoimmunity, lymphoproliferation, susceptibility to viral infections including SARS-CoV-2 and Epstein-Barr virus (EBV), and certain malignancies.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

TNFRSF13B is located on the short arm of chromosome 17 at cytogenetic band 17p11.2. The gene spans approximately 17.5 kilobases (kb) of genomic DNA and is oriented on the minus strand (reverse orientation) relative to the chromosome. The genomic coordinates (GRCh38/hg38) are approximately chr17:16,847,000–16,864,500. The gene consists of 3 exons and 2 introns, with the coding sequence distributed across all three exons. The mature mRNA transcript is approximately 1.4 kb in length and encodes a protein of 293 amino acids.

The genomic organization is relatively compact, with the following exon-intron architecture:

The promoter region of TNFRSF13B lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for transcription factors critical to B-cell development, including Pax5, E2A (TCF3), PU.1, and NF-κB. A functional enhancer element has been identified in the first intron, which is essential for B-cell-specific expression. This enhancer contains binding motifs for IRF4 and SPI-B, which cooperate to drive high-level expression in mature B cells and plasma cells. Disruption of this enhancer region by genetic variants has been shown to reduce TNFRSF13B expression and increase susceptibility to EBV-negative lymphoma.

1.2 Promoter Architecture and Transcriptional Regulation

The proximal promoter spans approximately 1 kb upstream of the transcription start site (TSS). DNase I hypersensitivity assays and chromatin immunoprecipitation (ChIP) studies have identified several regulatory regions:

• Proximal promoter (-200 to +50 bp): Contains binding sites for Sp1, Ets family members, and Ikaros. This region is constitutively active in B cells but repressed in non-hematopoietic tissues.
• Distal promoter (-1000 to -200 bp): Contains a STAT6 binding site, which mediates IL-4-induced upregulation of TACI expression. This is functionally significant because IL-4 promotes TACI expression during T-helper type 2 (Th2) responses, enhancing IgE class switching.
• Intronic enhancer (intron 1): A 200-bp region with conserved binding sites for IRF4 and PU.1. This enhancer is required for maximal expression in germinal center B cells and is silenced in T cells and myeloid cells.

A genome-wide association study (GWAS) identified the common variant rs4792800 (A>G) located within this intronic enhancer region. The G allele disrupts an IRF4 binding motif, reducing enhancer activity and TNFRSF13B expression in B cells. This variant is associated with increased risk of EBV-negative diffuse large B-cell lymphoma, demonstrating the functional importance of this regulatory element.

1.3 Alternative Splicing and Isoforms

Alternative splicing of TNFRSF13B generates multiple transcript variants. The two most extensively characterized isoforms are:

1. TACI-I (full-length, 293 aa): The canonical isoform containing both cysteine-rich domains (CRD1 and CRD2), the transmembrane domain, and the cytoplasmic tail. This isoform is the predominant form on naive and memory B cells.

1. TACI-II (isoform 2, 247 aa): Generated by alternative splicing that skips a portion of exon 2, resulting in deletion of the second cysteine-rich domain (CRD2). This isoform retains ligand-binding capacity for APRIL but has reduced affinity for BAFF. TACI-II is expressed at higher levels in activated B cells and plasma cells.

1. TACI-III (isoform 3): A rare splice variant lacking the transmembrane domain, resulting in a soluble form of TACI that can act as a decoy receptor. This isoform is expressed at very low levels in healthy individuals but may be upregulated in certain pathological conditions.

The balance between TACI-I and TACI-II isoforms is regulated by SRSF1 and hnRNP A1, which bind to exonic splicing enhancers and silencers in exon 2. Variants in TNFRSF13B that disrupt these splicing regulatory elements can shift the isoform ratio, leading to impaired B-cell function. For instance, the c.310T>C (p.Cys104Arg) variant, one of the most common pathogenic mutations, has been shown to alter splicing efficiency and reduce TACI-I expression.

1.4 Evolutionary Conservation

TNFRSF13B is highly conserved among vertebrates. Orthologs have been identified in all mammals, birds, amphibians, and fish. The cysteine-rich domains show the highest degree of conservation, with >90% amino acid identity between human and mouse TACI. The cytoplasmic tail is less conserved but contains a conserved TNFR-associated factor (TRAF)-binding motif (PxQxT) that is essential for signal transduction. Evolutionary analysis suggests that TACI emerged through gene duplication of an ancestral TNF receptor gene approximately 450 million years ago, coinciding with the evolution of the adaptive immune system.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Organization

The TACI protein is a 293-amino-acid type III transmembrane protein (no cleavable signal peptide) with the following domain architecture from N-terminus to C-terminus:

2.2 Extracellular Domain (ECD)

The ECD of TACI contains two cysteine-rich domains (CRDs), a hallmark of the TNF receptor superfamily. Each CRD consists of approximately 40 amino acids stabilized by three disulfide bonds, forming a characteristic "ligand-binding cradle" structure.

CRD1 (residues 32–71): This domain is primarily responsible for APRIL binding. The crystal structure of the TACI-APRIL complex (PDB: 1XUT) reveals that CRD1 forms a hydrophobic groove that accommodates the APRIL trimer. Key residues include Cys104 (the site of the most common pathogenic mutation, C104R), which forms a disulfide bond with Cys93. Substitution of this cysteine disrupts the CRD1 fold, abolishing APRIL binding.

CRD2 (residues 72–110): This domain mediates BAFF binding. Structural studies show that CRD2 interacts with the BAFF trimer through a distinct binding interface involving residues Arg84, His86, and Tyr88. The Ala181 residue (site of the A181E mutation) is located in the stalk region adjacent to CRD2; the A181E substitution introduces a charged residue that disrupts the local hydrophobic environment, impairing BAFF-induced signaling.

2.3 Transmembrane and Cytoplasmic Domains

The transmembrane domain (residues 167–187) is a single-pass hydrophobic α-helix. Unlike many TNF receptors that contain cytoplasmic death domains, TACI has a short cytoplasmic tail (residues 188–293) lacking enzymatic activity. Instead, signal transduction is mediated through recruitment of adaptor proteins:

• TRAF-binding motif (residues 240–244): The sequence P240-Q241-E242-T243 binds TRAF2, TRAF5, and TRAF6. This interaction is essential for activating the NF-κB and MAPK pathways.
• CAML-binding region (residues 188–220): TACI was originally identified through its interaction with the calcium-modulating cyclophilin ligand (CAML). The CAML-binding domain overlaps with the membrane-proximal region of the cytoplasmic tail and is required for calcium mobilization and activation of the transcription factor NF-AT.
• PKC phosphorylation sites: Serine residues at positions 228, 231, and 235 are substrates for protein kinase C (PKC). Phosphorylation of these residues modulates TRAF recruitment and receptor internalization.

2.4 Quaternary Structure

TACI exists as a pre-formed homotrimer on the cell surface, even in the absence of ligand. This trimeric assembly is mediated by interactions between the stalk regions of three monomers. Ligand binding (BAFF or APRIL, which are themselves trimers) induces a conformational change that brings the cytoplasmic tails into close proximity, facilitating TRAF recruitment.

Crystal structures of the TACI ECD in complex with BAFF (PDB: 1XU1) and APRIL (PDB: 1XUT) reveal a 3:3 stoichiometry, with each TACI monomer binding to one subunit of the ligand trimer. The binding affinity (Kd) is approximately 1–10 nM for APRIL and 10–50 nM for BAFF, with APRIL showing higher affinity due to additional contacts with CRD1.

2.5 Post-Translational Modifications

TACI undergoes several post-translational modifications that regulate its function:

• N-linked glycosylation: Two N-glycosylation sites (Asn78 and Asn110) in the ECD are required for proper folding and cell-surface expression. Inhibition of glycosylation reduces TACI surface levels by 50%.
• O-linked glycosylation: Multiple O-glycosylation sites in the stalk region (Thr116, Ser120, Thr124) modulate ligand binding affinity and protect the receptor from proteolytic cleavage.
• Proteolytic shedding: TACI is cleaved by the metalloprotease ADAM17 (TACE) at a site near the transmembrane domain, releasing a soluble form (sTACI) that can neutralize BAFF and APRIL. This shedding is enhanced by B-cell receptor (BCR) stimulation and provides a negative feedback mechanism.

2.6 Interactive 3D Visualization

Interactive 3D Protein Visualizer: Load TNFRSF13B (PDB: true)

The interactive visualizer allows exploration of the TACI structure, including the CRD1 and CRD2 domains, the ligand-binding interfaces, and the location of clinically significant mutations. Users can toggle between the apo form and the BAFF/APRIL-bound conformations to observe ligand-induced conformational changes.

3. Cellular Signaling Pathways & Molecular Function

3.1 Ligand-Receptor Interactions

TACI binds two TNF superfamily ligands:

1. BAFF (B-cell activating factor; TNFSF13B): A type II transmembrane protein that is cleaved to release a soluble trimeric form. BAFF is produced by myeloid cells, neutrophils, and stromal cells. It signals through three receptors: TACI, BAFF-R (TNFRSF13C), and BCMA (TNFRSF17).

1. APRIL (a proliferation-inducing ligand; TNFSF13): A ligand that shares significant homology with BAFF. APRIL is produced by dendritic cells, monocytes, and tumor cells. It signals exclusively through TACI and BCMA.

The differential expression of these ligands and receptors creates a complex regulatory network. BAFF-R is the primary survival receptor for transitional and naive B cells, while TACI is more important for T-independent antibody responses and plasma cell differentiation. BCMA is predominantly expressed on plasma cells and supports their long-term survival.

3.2 Signal Transduction Cascades

Upon ligand binding, TACI trimerizes and recruits TRAF proteins to its cytoplasmic tail. This initiates multiple signaling cascades:

sequenceDiagram
    participant L as "BAFF/APRIL trimer"
    participant T as "TACI (trimer)"
    participant TR as "TRAF2/5/6"
    participant IKK as "IKK complex"
    participant NF as "NF-κB (p50/p65)"
    participant N as "Nucleus"
    participant A as "AID (activation-induced cytidine deaminase)"
    participant P as "Plasma cell differentiation genes"
    L->>T: Ligand binding
    T->>TR: TRAF recruitment
    TR->>IKK: Activation of IKK complex
    IKK->>NF: IκBα phosphorylation & degradation
    NF->>N: Nuclear translocation
    N->>A: AID upregulation
    A->>P: Class switch recombination (CSR)
    N->>P: IRF4, Blimp-1, XBP1 activation

Canonical NF-κB pathway: TRAF2 and TRAF6 recruit the IKK complex (IKKα/IKKβ/NEMO), leading to phosphorylation and ubiquitin-mediated degradation of IκBα. This releases NF-κB (p50/p65 heterodimer) for nuclear translocation, where it drives expression of genes involved in B-cell activation, survival, and isotype switching.

Non-canonical NF-κB pathway: TRAF2 also activates NIK (NF-κB-inducing kinase), which phosphorylates IKKα, leading to processing of p100 to p52. The p52/RelB complex translocates to the nucleus and regulates a distinct set of genes, including those involved in plasma cell differentiation.

MAPK pathways: TRAF6 activates the MAPK cascade (ERK, JNK, p38) through TAK1. These pathways contribute to AP-1 transcription factor activation and cytokine production.

CAML-dependent calcium signaling: TACI interacts with CAML, which recruits the calcium channel IP3R to the receptor complex. This leads to calcium mobilization and activation of the transcription factor NF-AT, which cooperates with NF-κB to drive AID expression.

3.3 Functional Outcomes

Class switch recombination (CSR): TACI signaling upregulates AID expression, which is essential for CSR. TACI promotes switching to IgA and IgG isotypes, particularly in response to T-independent antigens. TACI-deficient mice and humans with TNFRSF13B mutations show impaired IgA and IgG responses to polysaccharide antigens.

Plasma cell differentiation: TACI signaling induces expression of the transcription factors IRF4, Blimp-1, and XBP1, which drive the differentiation of activated B cells into antibody-secreting plasma cells. TACI also promotes plasma cell survival by upregulating anti-apoptotic genes such as MCL1 and BCL2.

Negative regulation of B-cell expansion: TACI has a unique role in counteracting BAFF-R-mediated B-cell survival. TACI signaling induces apoptosis in autoreactive B cells and limits BAFF-driven B-cell expansion. This is mediated through upregulation of the pro-apoptotic protein BIM and downregulation of the survival factor BAFF-R. TACI deficiency therefore leads to B-cell accumulation and autoimmunity.

T-independent antibody responses: TACI is essential for antibody responses to T-independent type 2 (TI-2) antigens, such as bacterial polysaccharides. TACI-deficient mice fail to produce antibodies against pneumococcal polysaccharide, and humans with TNFRSF13B mutations show impaired responses to pneumococcal vaccines.

3.4 Protein-Protein Interaction Network

TACI participates in a complex interaction network involving both membrane-bound and intracellular proteins:

The interaction between TACI and MyD88 is particularly notable, as it links TACI signaling to Toll-like receptor (TLR) pathways. This interaction is required for TACI-mediated CSR in response to T-independent antigens and explains why TACI mutations can impair responses to both protein and polysaccharide antigens.

3.5 Regulation of TACI Expression

TACI expression is dynamically regulated during B-cell development:

• Pro-B and pre-B cells: Low expression
• Naive mature B cells: Moderate expression
• Germinal center B cells: High expression (induced by CD40L and IL-4)
• Memory B cells: High expression
• Plasma cells: Variable expression (downregulated in long-lived bone marrow plasma cells)

TACI expression is upregulated by CD40L, IL-4, IL-10, and BAFF itself, creating a positive feedback loop. Conversely, TACI is downregulated by BCR crosslinking and TLR9 stimulation, which promote plasma cell differentiation and terminal differentiation.

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Spectrum of TNFRSF13B Variants

TNFRSF13B is one of the most frequently mutated genes in primary immunodeficiency, with pathogenic or likely pathogenic variants identified in approximately 8–10% of CVID patients and 5–8% of IgAD patients. However, the interpretation of TNFRSF13B variants is complicated by the fact that:

1. Incomplete penetrance: Many variants are found in healthy individuals at frequencies of 1–2% in the general population.
2. Variable expressivity: The same variant can cause CVID in one family member and be asymptomatic in another.
3. Autosomal dominant and recessive inheritance: Both modes of inheritance have been described, with dominant inheritance showing incomplete penetrance.
4. Oligogenic inheritance: TNFRSF13B variants often act in concert with variants in other immune genes (e.g., TCF3, CTLA4, ICOS) to produce clinical disease.

4.2 Major Pathogenic Hotspots

The following variants are the most frequently reported pathogenic mutations:

p.Cys104Arg (C104R): This is the most common pathogenic variant, accounting for approximately 40% of TNFRSF13B mutations in CVID patients. The substitution of a cysteine residue disrupts a critical disulfide bond in CRD1, leading to misfolding and loss of APRIL binding. Heterozygous carriers show haploinsufficiency, with reduced TACI expression on B cells. Multi-omics analysis of naive B cells from C104R carriers reveals dysregulation of genes involved in B-cell activation, apoptosis, and plasma cell differentiation. Mouse models carrying the equivalent C76R mutation show impaired T-independent antibody responses and reduced plasma cell survival.

p.Ala181Glu (A181E): The second most common variant, A181E is located in the stalk region adjacent to CRD2. This mutation impairs BAFF binding and disrupts TACI trimerization. Clinical phenotypes are highly variable, ranging from asymptomatic carriers to severe CVID with autoimmune complications. The A181E variant shows particularly strong association with autoimmune cytopenias and lymphoproliferation.

p.Gly76Ser (G76S): This variant was initially identified in CVID patients but has recently been implicated as a causative mutation for pulmonary arterial hypertension (PAH). The G76S substitution is located in CRD1 and affects ligand binding. Functional studies show that this variant impairs TACI-mediated NF-κB activation and reduces B-cell survival. The association with PAH suggests that TACI signaling may have roles beyond the immune system, possibly in vascular endothelial cells.

4.3 Clinical Phenotypes and Differential Diagnosis

Common Variable Immunodeficiency (CVID): CVID is the most common symptomatic primary immunodeficiency, with an estimated prevalence of 1:25,000. The diagnosis requires:

• Marked reduction in IgG, IgA, and/or IgM (at least 2 SD below the mean for age)
• Poor or absent response to vaccines
• Exclusion of other causes of hypogammaglobulinemia

Patients with TNFRSF13B mutations typically present with:

• Recurrent bacterial infections, particularly of the respiratory tract (sinusitis, otitis media, pneumonia)
• Encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae)
• Autoimmune complications (cytopenias, autoimmune thyroiditis, inflammatory bowel disease)
• Lymphoproliferation (splenomegaly, lymphadenopathy)
• Increased risk of lymphoma and gastric cancer

IgA deficiency (IgAD): Defined as serum IgA < 0.07 g/L with normal IgG and IgM. TNFRSF13B mutations are found in 5–8% of IgAD patients. Many patients are asymptomatic, but some develop recurrent infections, autoimmune diseases, and allergic disorders.

Autoimmune lymphoproliferative syndrome (ALPS)-like phenotype: Some TNFRSF13B mutations have been associated with ALPS-like features, including chronic lymphadenopathy, splenomegaly, and autoimmune cytopenias.

Pulmonary arterial hypertension (PAH): The G76S variant has been identified as a novel causative mutation for PAH, expanding the phenotypic spectrum beyond immunodeficiency.

Hematological malignancies: TNFRSF13B mutations have been identified in patients with:

• Acute myeloid leukemia (AML), including familial cases
• Hodgkin lymphoma
• Diffuse large B-cell lymphoma
• Chronic lymphocytic leukemia (CLL)

Infectious disease susceptibility:

• SARS-CoV-2: TNFRSF13B polymorphisms (rs12603708, rs11078355) are associated with susceptibility to SARS-CoV-2 infection and severity of COVID-19. A case of lethal COVID-19 in a child with compound TNFRSF13B and TBK1 mutations has been reported.
• Epstein-Barr virus (EBV): TNFRSF13B exon 2 variants are recurrently identified in chronic active EBV disease (CAEBV) and EBV-associated lymphoproliferative disorders.
• Invasive fungal infections: TNFRSF13B mutations increase susceptibility to invasive fungal infections, particularly in patients undergoing chemotherapy for AML.

4.4 Genotype-Phenotype Correlations

A comprehensive re-evaluation of TNFRSF13B variants in antibody deficiency established several important genotype-phenotype correlations:

1. Biallelic (homozygous or compound heterozygous) mutations cause more severe disease with earlier onset, more profound hypogammaglobulinemia, and higher rates of autoimmune complications.
2. Monoallelic mutations show incomplete penetrance (~30-50%) and are often found in asymptomatic carriers. The penetrance is influenced by the specific variant, with C104R showing higher penetrance than A181E.
3. Variants affecting the CRD domains (C104R, G76S) are more likely to cause clinical disease than variants in the cytoplasmic tail.
4. The presence of additional variants in other immune genes (e.g., TCF3, CTLA4) increases penetrance and severity, supporting an oligogenic model of inheritance.

4.5 Clinical Differentials

When evaluating a patient with suspected TNFRSF13B-related disease, the following differential diagnoses should be considered:

5. Host-Pathogen & Viral Interactions

5.1 Epstein-Barr Virus (EBV) Interactions

EBV is a gamma-herpesvirus that establishes lifelong latency in B cells. TNFRSF13B variants have been implicated in the pathogenesis of EBV-associated diseases through multiple mechanisms:

Chronic active EBV disease (CAEBV): Exon 2 variants of TNFRSF13B are recurrently identified in patients with CAEBV. These variants cause imbalanced expression of TACI isoforms, with increased TACI-II (which lacks CRD2) relative to TACI-I. This imbalance impairs the ability of B cells to control EBV infection and promotes the expansion of EBV-infected cells.

EBV-associated lymphoproliferative diseases (EBV-LPDs): TNFRSF13B variants that disrupt the intronic enhancer (rs4792800) reduce TACI expression and increase susceptibility to EBV-negative lymphoma. In EBV-positive LPDs, the virus exploits TACI signaling to promote B-cell survival and proliferation. The EBV-encoded latent membrane protein 1 (LMP1) mimics CD40 signaling and synergizes with TACI to activate NF-κB, driving uncontrolled B-cell expansion.

Mechanism of immune evasion: EBV upregulates BAFF expression in infected B cells, creating an autocrine survival loop that is partially dependent on TACI. In patients with TNFRSF13B mutations, this loop is dysregulated, leading to either excessive B-cell survival (in the case of gain-of-function variants) or impaired immune control (in the case of loss-of-function variants).

5.2 SARS-CoV-2 Interactions

TNFRSF13B polymorphisms influence susceptibility to SARS-CoV-2 infection and the severity of COVID-19. The rs12603708 and rs11078355 variants are associated with:

• Increased risk of SARS-CoV-2 infection
• More severe disease requiring hospitalization
• Impaired humoral immune response with reduced neutralizing antibody titers

The mechanism involves reduced TACI expression on B cells, leading to:

• Impaired class switch recombination to IgG and IgA
• Reduced plasma cell differentiation
• Decreased production of virus-specific antibodies

A case of lethal COVID-19 in a 3.5-year-old girl with compound heterozygous mutations in TNFRSF13B and TBK1 has been reported. The child had an autoinflammatory disorder of unknown etiology, and the combination of impaired innate (TBK1) and adaptive (TNFRSF13B) immunity resulted in severe disease.

5.3 Bacterial Pathogens

TNFRSF13B mutations increase susceptibility to infections with encapsulated bacteria, particularly:

• Streptococcus pneumoniae: Patients with TNFRSF13B mutations show impaired antibody responses to pneumococcal polysaccharide vaccines and are at increased risk of invasive pneumococcal disease, including meningitis.
• Haemophilus influenzae type b: Impaired T-independent antibody responses increase susceptibility to this pathogen.
• Mycobacterium bovis (BCG): Disseminated BCG infection has been reported in infants with primary immunodeficiency, including those with TNFRSF13B mutations.

5.4 Fungal Pathogens

TNFRSF13B mutations increase susceptibility to invasive fungal infections, particularly in immunocompromised patients. A case report described a patient with AML and a TNFRSF13B mutation who developed invasive fungal infection during chemotherapy. The impaired B-cell function and hypogammaglobulinemia associated with TNFRSF13B mutations likely contribute to defective antifungal immunity.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Immunoglobulin Replacement Therapy

The primary treatment for patients with TNFRSF13B-associated CVID is intravenous or subcutaneous immunoglobulin (IVIG/SCIG) replacement therapy. This provides passive immunity and reduces the frequency and severity of bacterial infections. IVIG is typically administered at a dose of 400–600 mg/kg every 3–4 weeks, with dose adjustments based on trough IgG levels and clinical response.

6.2 Antibiotic Prophylaxis

Patients with recurrent bacterial infections may benefit from prophylactic antibiotics, particularly those with impaired responses to pneumococcal vaccines. Common regimens include:

• Amoxicillin 250–500 mg twice daily
• Azithromycin 250 mg three times weekly
• Trimethoprim-sulfamethoxazole 80/400 mg daily

6.3 BAFF/APRIL-Targeted Therapies

Given the central role of the BAFF/APRIL system in B-cell biology, several therapeutic agents targeting this pathway have been developed:

Atacicept and telitacicept are particularly relevant to TNFRSF13B, as they are engineered TACI-Fc fusion proteins that act as soluble decoy receptors. These agents sequester BAFF and APRIL, preventing them from engaging membrane-bound TACI, BAFF-R, and BCMA. In IgA nephropathy (IgAN), atacicept has shown promise in reducing proteinuria and stabilizing renal function by reducing IgA production.

6.4 Targeted Therapies for Malignancies

For patients with TNFRSF13B mutations who develop lymphoma or other malignancies, treatment approaches include:

• Rituximab (anti-CD20): Depletes B cells, including malignant cells. However, this can exacerbate immunodeficiency and increase infection risk.
• BTK inhibitors (ibrutinib, acalabrutinib): Target B-cell receptor signaling, which is important for B-cell survival and proliferation.
• CAR-T cell therapy: Chimeric antigen receptor T cells targeting CD19 or CD22 have shown efficacy in relapsed/refractory B-cell malignancies.
• Checkpoint inhibitors (pembrolizumab, nivolumab): May be effective in EBV-associated lymphomas, which often express PD-L1.

6.5 Gene Therapy

Gene therapy approaches for TNFRSF13B deficiency are in preclinical development. The relatively small size of the TNFRSF13B coding sequence (879 bp) makes it amenable to delivery via adeno-associated virus (AAV) vectors or lentiviral vectors. However, challenges include:

• Achieving B-cell-specific expression
• Avoiding insertional mutagenesis
• Maintaining appropriate regulation of expression

6.6 Pharmacogenomic Considerations

TNFRSF13B genotype may influence responses to immunomodulatory therapies:

• Belimumab: Patients with TNFRSF13B mutations may show altered responses to BAFF neutralization, as TACI-mediated signaling is already impaired.
• IVIG: Patients with TNFRSF13B mutations may require higher doses of IVIG due to impaired endogenous antibody production.
• Immunosuppressants: Caution is required when using immunosuppressive agents in patients with TNFRSF13B mutations, as these may exacerbate immunodeficiency.

7. Bioinformatic Resources & Database Accessions

| HGMD | Gene: TNFRSF13B | http://www.hgmd.cf.ac.uk/ac

Related Clinical & Scientific Guides

• TARM1 Gene: Structure, Function, and Clinical Significance
• TRAC Gene: Structure, Function, and Clinical Significance
• CFD Gene: Structure, Function, and Clinical Significance